Conclusions Overall, the study suggested that GLP-1 agonists, particularly liraglutide and semaglutide, were promising options for reducing AUD-related hospitalizations
BMC Med Educ (2021) 21(1):111
The cohort also had a high mean BMI (39.6 kg/m 2 ), with 65% having obesity (BMI 35 kg/m 2 ), in line with NICE recommendations for the initiation of GLP-1 RAs [6]
Experts say semaglutide, which is injected once a week, can come with some side-effects like fatigue and digestion problems but the benefits outweigh the risks for patients at risk of obesity-related risks like heart disease
Perfect for lunch, dinner or post-gym recovery
Found in plants such as barberry and goldenseal, this bright yellow alkaloid has been used for centuries in traditional medicine and is now backed by modern research for its wide-ranging health benefits